Mario Garretto, MD
Gastroenterology · Kenosha, WINPI 1497701809
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 27.6% of the total.
Across 290 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Gilead$1K
- Johnson & Johnson$915
- Takeda Pharmaceuticals U.S.A., Inc.$323
- Pfizer$317
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$264
- plus $1K from 24 others
What the payments were for
- Food & beverage$5,50593%
- Education$4217%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,635 |
| Gilead | 57 | $1,076 |
| Johnson & Johnson | 33 | $915 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $323 |
| Pfizer | 29 | $317 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $264 |
| Braintree Laboratories, Inc. | 8 | $183 |
| UCB, Inc. | 4 | $149 |
| Medical Device Business Services, Inc. | 3 | $148 |
| Daiichi Sankyo Inc. | 7 | $127 |
| Bristol Myers Squibb | 6 | $122 |
| Ironwood Pharmaceuticals, Inc | 7 | $111 |
| Janssen Scientific Affairs, LLC | 1 | $85 |
| Aimmune Therapeutics, Inc. | 2 | $57 |
| Madrigal Pharmaceuticals | 3 | $56 |
| Sandoz | 2 | $40 |
| Ardelyx, Inc. | 2 | $35 |
| Celltrion USA Inc. | 2 | $35 |
| Evoke Pharma, Inc. | 2 | $35 |
| Shionogi Inc | 2 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Sanofi | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Intercept Pharmaceuticals, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Vivus LLC | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,927 in reported general payments places this provider in the 85th percentile of 285 gastroenterology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 24 | $60,989 |
| LinzessLinaclotide | 42 | $39,818 |
| Mesalamine | 48 | $18,596 |
| Omeprazole | 604 | $7,303 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 29 | $4,776 |
| Famotidine | 67 | $4,533 |
| CholestyramineCholestyramine (With Sugar) | 35 | $3,719 |
| Dexlansoprazole DrDexlansoprazole | 16 | $3,401 |
| Pantoprazole Sodium | 276 | $3,322 |
| Sucralfate | 18 | $3,132 |
| Mesalamine ErMesalamine | 11 | $3,130 |
| Budesonide DrBudesonide | 25 | $2,966 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 36 | $2,229 |
| Dicyclomine Hcl | 46 | $1,989 |
| Lansoprazole | 14 | $1,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $264 | $60,98924 claims |
| AbbVieLinzess | $1,635 | $39,81842 claims |
| Braintree Laboratories, Inc.Sutab | $183 | $4,77629 claims |
| SandozLansoprazole | $40 | $1,79014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 285 gastroenterology providers in Wisconsin.
Other gastroenterology in Kenosha
- Daniel SteinMilwaukee$227K
- Amir PatelSheboygan$137K
- Poonam Beniwal-PatelMilwaukee$108K
- Lilani PereraMequon$95K
- Freddy CalderaMadison$72K
- Matthew PellerMilwaukee$63K
- Susan LepinskiMadison$61K
- Chetan MittalMilwaukee$53K
- Pedro Palacios ArguetaEau Claire$53K
- Patrick SanvansonMilwaukee$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.